Rohrbach J M, Stiemer R, Mayer A, Riedinger C, Duijvestijn A, Zierhut M
University Eye Clinic, Kiel, Germany.
Graefes Arch Clin Exp Ophthalmol. 2001 Jan;239(1):35-40. doi: 10.1007/s004170000221.
Knowledge about immunological features and growth characteristics of palpebral (ocular) basal cell carcinomas (BCCs) is limited. In particular, it is unclear whether ocular BCC represents in this regard a special BCC entity or not.
Twenty BCCs of the lid area (ocular BCCs) were investigated immunohistologically using monoclonal antibodies against CD4, CD8, CD45Ro, CD50, CD68, HECA-452, Ki67 (MIB1), and the p53 epitope. For comparison, nine BCCs excised distant from the eye (non-ocular BCCs) were evaluated.
In BCCs the distribution of the immunocompetent cells investigated is markedly irregular. These cells are localized mainly around BCC islands. Only a few of them invade tumour cell aggregates. The CD4:CD8 ratio as detected by immunohistochemistry is >1 in 82% of ocular BCCs and in 88% of nonocular BCCs. Often there are dense infiltrations of CD68+ cells (macrophages) and HECA-452+ cells adjacent to tumour cell aggregates. The growth fraction [percentage of proliferating (Ki67+/MIB 1+) cells] varies from 0% to more than 30%. Proliferative activity is enhanced at the invasion front. Additionally, the amount of p53+ cells differs considerably among the BCCs.
CD4+ T cells seem to be the most important cell population for BCC immunosurveillance, offering the chance for conservative interferon therapy. The role of CD68+ and HECA-452+ cells has to be further elucidated. In many tumours the large amount of proliferating cells contrasts to the usually slow growth of BCCs, indicating strong apoptotic processes. The results can be regarded only as semiquantitative. So far, ocular and nonocular BCCs exhibit no essential differences regarding immunocompetent cell infiltration and growth characteristics. According to this, palpebral BCCs are "normal" BCCs and not a special BCC variant. Therefore, results from dermatological research concerning BCC can be extended without limitations to their counterparts in the lid area.
关于睑（眼）部基底细胞癌（BCC）的免疫特征和生长特性的知识有限。特别是，眼部BCC在这方面是否代表一种特殊的BCC实体尚不清楚。
使用针对CD4、CD8、CD45Ro、CD50、CD68、HECA-452、Ki67（MIB1）和p53表位的单克隆抗体，对20例眼睑区域的BCC（眼部BCC）进行免疫组织学研究。为作比较，评估了9例远离眼部切除的BCC（非眼部BCC）。
在BCC中，所研究的免疫活性细胞分布明显不规则。这些细胞主要位于BCC岛周围。只有少数细胞侵入肿瘤细胞聚集体。免疫组织化学检测到的CD4:CD8比值在82%的眼部BCC和88%的非眼部BCC中>1。肿瘤细胞聚集体附近常可见CD68+细胞（巨噬细胞）和HECA-452+细胞的密集浸润。生长分数[增殖（Ki67+/MIB1+）细胞的百分比]从0%到超过30%不等。增殖活性在侵袭前沿增强。此外，BCC中p53+细胞的数量差异很大。
CD4+T细胞似乎是BCC免疫监视中最重要的细胞群，为保守性干扰素治疗提供了机会。CD68+和HECA-452+细胞的作用有待进一步阐明。在许多肿瘤中，大量增殖细胞与BCC通常缓慢的生长形成对比，表明存在强烈的凋亡过程。这些结果只能视为半定量的。到目前为止，眼部和非眼部BCC在免疫活性细胞浸润和生长特性方面没有本质区别。据此，睑部BCC是“普通”的BCC，而非特殊的BCC变体。因此，皮肤病学关于BCC的研究结果可以无限制地推广到眼睑区域的同类疾病。
